Bellicum 
Welcome,         Profile    Billing    Logout  
 10 Products   13 Diseases  10 Products   19 Trials   822 News 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) / Bellicum
NCT01744223: Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Active, not recruiting
1/2
36
US
BPX-501 dose 1, rivogenlecleucel, Rimiducid, AP1903, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
10/19
10/32
NCT02065869 / 2014-000584-41: Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Checkmark Topline data from BP-004 trial
Jul 2019 - Jul 2019: Topline data from BP-004 trial
Checkmark From BP-004 trial in children with transfusion-dependent thalassemia [screenshot]
Dec 2018 - Dec 2018: From BP-004 trial in children with transfusion-dependent thalassemia [screenshot]
Checkmark From BP-004 trial in children with acute leukemia at ASH 2018 [screenshot]
More
Terminated
1/2
187
Europe
BPX-501 T cells, Rivogenlecleucel, Rimiducid, AP1903
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome, Primary Immunodeficiency, Anemia, Aplastic, Osteopetrosis, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell
06/20
09/21
NCT03733249 / 2016-003226-16: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Terminated
1/2
187
Europe
Rimiducid, AP1903, rivogenlecleucel, BPX-501
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immunodeficiency, Anemia, Aplastic, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell
06/20
04/23
NCT03301168: Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Checkmark From trials in children with malignant or non-malignant disorders who develop GVHD at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From trials in children with malignant or non-malignant disorders who develop GVHD at ASH 2018 [screenshot]
Active, not recruiting
1/2
120
US
BPX-501 T cells, rivogenlecleucel, Rimiducid, AP1903
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic
05/21
05/34
NCT03056339: Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Completed
1/2
49
US
Fludarabine, Fludarabine phosphate, Fludara, Cyclophosphamide, Cytoxan, Neosar, Mesna, Mesnex, iC9/CAR.19/IL15-Transduced CB-NK Cells, NK cells, AP1903
M.D. Anderson Cancer Center
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
03/23
03/23
NCT02231710: Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

Terminated
1
1
US
BPX-501 and Rimiducid
Bellicum Pharmaceuticals
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
09/15
01/18
NCT02477878: Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Active, not recruiting
1
10
US
BPX-501, Rimiducid, AP1903
Bellicum Pharmaceuticals
Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
01/20
01/33
NCT03459170 / 2015-005176-17: Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Active, not recruiting
1
15
Europe
BPX-501 T cells, rivogenlecleucel, rimiducid, AP1903
Bellicum Pharmaceuticals
Hematologic Malignancy
09/22
09/35
NCT03639844: BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

No Longer Available
N/A
US
rivogenlecleucel, BPX-501 T cells, rimiducid, AP1903, Rimiducid for Injection, AP1903 for Injection
Bellicum Pharmaceuticals
Hurler Syndrome, Inherited Metabolic Disorder, Lysosomal Storage Disorder, Metachromatic Leukodystrophy, Inborn Errors of Metabolism
 
 
BPX-601 / Bellicum
NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Feb 2023 - Feb 2023: Early P1 data in patients with metastatic castration-resistant prostate cancer at ASCO-GU 2023
Checkmark Updated data from BP-012 trial
Oct 2020 - Oct 2020: Updated data from BP-012 trial
Checkmark From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
May 2019 - Jun 2019: From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
More
Suspended
1/2
151
US
BPX-601, Rimiducid, AP1903
Bellicum Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
10/25
02/26
iCasp9M28z T cell infusion / Memorial Sloan-Kettering Cancer Center, Bellicum
NCT02414269: Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Active, not recruiting
1/2
113
US
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Memorial Sloan Kettering Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
04/25
04/25
rimiducid (AP1903) / Bellicum
NCT03016377: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Recruiting
1/2
54
US
iC9-CAR19 cells, CAR.CD19 T cells, Rimiducid, AP1903, Cyclophosphamide, Neosar, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, The Leukemia and Lymphoma Society
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
04/26
04/41
2021-004729-55: Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory central nervous system tumors Studio di fase I su cellule T esprimenti un recettore chimerico anti-GD2 in pazienti pediatrici e giovani adulti affetti da tumori al sistema nervoso centrale recidivati/refrattari

Not yet recruiting
1
27
Europe
GD2-CART01, Ciclofosfamide monoidrata, AP1903, Fludarabina Fosfato, [GD2-CART01], [n.a], Solution for infusion, Powder and solvent for solution for infusion
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
Relapsed/refractory malignant central nervous system tumors Tumori maligni al sistema nervoso centrale recidivati/refrattari, Relapsed/refractory malignant central nervous system tumors Tumori maligni al sistema nervoso centrale recidivati/refrattari, Diseases [C] - Cancer [C04]
 
 
NCT04249947: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Checkmark Interim results from P1 trial in mCRPC at ASCO-GU 2022
Feb 2022 - Feb 2022: Interim results from P1 trial in mCRPC at ASCO-GU 2022
Active, not recruiting
1
60
US
P-PSMA-101 CAR-T cells, Rimiducid
Poseida Therapeutics, Inc.
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
10/24
09/36
NCT02792114: T-Cell Therapy for Advanced Breast Cancer

Active, not recruiting
1
186
US
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Memorial Sloan Kettering Cancer Center, United States Department of Defense
Breast Cancer, Metastatic HER2-negative Breast
06/25
06/25
NCT06358430: Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Not yet recruiting
1
42
US
Fludarabine Phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, Cetuximab, C225, Erbitux™, IMC-C225, MOAB C225, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy
M.D. Anderson Cancer Center, Bellicum Pharmaceuticals, Inc.
Colorectal Cancer, Minimal Residual Disease
01/29
01/29
P-BCMA-ALLO1-001, NCT04960579: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Recruiting
1
231
US
P-BCMA-ALLO1 CAR-T cells, Rimiducid
Poseida Therapeutics, Inc., Roche-Genentech
Multiple Myeloma
12/27
12/39
P-MUC1C-ALLO1-001, NCT05239143: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Recruiting
1
180
US
P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Poseida Therapeutics, Inc.
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
04/26
04/39
NCT03696784: Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Recruiting
1
30
US
iC9-CAR19 T cells, Bendamustine, Treanda, Bendeka, Fludarabine, Fludara, AP1903, Rimiducid, Cyclophosphamide, Cytoxan, Neosar
UNC Lineberger Comprehensive Cancer Center, UNC Chapel Hill University Cancer Research Fund, The V Foundation, M.D. Anderson Cancer Center
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
03/27
03/43
NCT06066424: Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Recruiting
1
54
US
Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center, Bellicum Pharmaceuticals
Solid Tumors
04/38
04/40
P-CD19CD20-ALLO1-001, NCT06014762: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Recruiting
1
120
US
P-CD19CD20-ALLO1, Rimiducid
Poseida Therapeutics, Inc., Roche-Genentech
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL), Follicular Lymphoma Grade 3B
03/29
03/41
DOTTI, NCT01494103: Administration of Donor T Cells With the Caspase-9 Suicide Gene

Active, not recruiting
1
15
US
iCaspase9-transduced T cells, AP1903, AP1903 Dimerizer Drug
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Non Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytosis, Familial Hemophagocytic Lymphohistiocytosis, Hemophagocytic Syndrome, Epstein Barr Virus Infection, X-linked Lymphoproliferative Disease
05/29
05/29
NCT03741127: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Active, not recruiting
1
100
US
Rimiducid may be administered as indicated, Rimiducid (safety switch activator)
Poseida Therapeutics, Inc., California Institute for Regenerative Medicine (CIRM)
Multiple Myeloma
08/32
11/32
NCT03594162: Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

No Longer Available
N/A
US
iC9-CAR19 cells, CAR.CD19 T cells, AP1903, Rimiducid, Cyclophosphamide, Neosar, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
 
 
BPX-603 / Bellicum
NCT04650451: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Suspended
1/2
220
US
chimeric antigen receptor (CAR) T cell therapy, CAR-T, BPX-603, autologous CAR-T
Bellicum Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
12/25
01/27
BCMA GoCAR-NK cell therapy / Bellicum
No trials found
anti-CD123 CAR T-cell therapy / Bellicum
No trials found

Download Options